Deep-Dive Due Diligence AI Generated Report on Forte Biosciences, Inc. Common Stock (FBRX)

Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.

These reports are generated using OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.

Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.


FBRX_OUT_1 [2025-03-19 12:36:22 -0400] 2168 Bytes | 627 tokens | Cum: 627 tkns (7.84% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Forte Biosciences (FBRX) which is at 6.42 up from 5.5. So, I pulled together a bunch of data for you to look over real fast. It's still early, 12:36:20 PM on Wednesday March 19, 2025 ET (UTC-0400). So, what's the verdict? You're the expert!

Here's the first list of news for Forte Biosciences:

C1 - Feb-03-25 09:00AM - Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
C2 - Nov-25-24 09:00AM - Forte Biosciences to Host RandD Day December 3, 2024
C3 - Nov-25-24 09:00AM 09:00AM - Forte Biosciences to Host R&D Day December 3, 2024
C4 - Nov-20-24 09:00AM - Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
C5 - Nov-14-24 04:01PM - Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
C6 - Aug-26-24 11:51AM - Upcoming Stock Splits This Week (August 26 to August 30) Stay Invested
C7 - Aug-14-24 09:54PM - FBRX Stock Earnings: Forte Biosciences Misses EPS for Q2 2024
C8 - Aug-14-24 09:54PM 04:01PM - Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Forte Biosciences (FBRX)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Forte Biosciences.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

FBRX_IN_2 [2025-03-19 12:36:22 -0400] 2 Bytes | 2 tokens | Cum: 629 tkns (7.86% of 8k)
==========================================================================

C4

FBRX_OUT_3 [2025-03-19 12:36:33 -0400] 481 Bytes | 130 tokens | Cum: 759 tkns (9.49% of 8k)
==========================================================================

Showing C4 (chunk 1 of 1): C4:
**Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications**
Date: Nov-20-24 09:00AM
Source: (Business Wire)
URL: https://www.businesswire.com/news/home/20241120549128/en/

Error fetching article: 403 Client Error: Forbidden for url: https://www.businesswire.com/news/home/20241120549128/en/

-- More? (MOR) or Next section? (NEX)

FBRX_IN_4 [2025-03-19 12:36:33 -0400] 1357 Bytes | 235 tokens | Cum: 994 tkns (12.43% of 8k)
==========================================================================

As a financial analyst, this announcement from Forte Biosciences, Inc. indicates a significant development. The company has successfully raised $53 million from an oversubscribed private placement. The funds are intended to advance the development of FB102 across various autoimmune indications.

The oversubscribed placement indicates strong investor interest in the company's direction and potential. This capital injection should strengthen Forte Biosciences' financial position, enabling it to invest more in the research and development of FB102, which could potentially lead to successful commercialization and revenue generation in the future.

However, the full details of the private placement, including the terms and potential dilution effect for existing shareholders, are not available due to an error fetching the article. It's important to review these details for a comprehensive understanding of the financial impact of this event.

Overall, this announcement could have a positive impact on Forte Biosciences' stock price subject to market conditions and investor sentiment. However, it's worth noting that the development and commercialization of pharmaceutical products involve significant risks and uncertainties. The ultimate effect on the company's financials will depend on the successful advancement and commercialization of FB102.

FBRX_OUT_5 [2025-03-19 12:36:35 -0400] 674 Bytes | 194 tokens | Cum: 1188 tkns (14.85% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-02-28T21:25:23Z - Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update...
A2 - 2025-02-20T07:51:59Z - Forte Biosciences Target of Unusually Large Options Trading (NASDAQ:FBRX)...
A3 - 2025-02-19T11:03:21Z - One Forte Biosciences Insider Raised Stake By 273% In Previous Year...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

FBRX_IN_6 [2025-03-19 12:36:35 -0400] 2 Bytes | 2 tokens | Cum: 1190 tkns (14.88% of 8k)
==========================================================================

A1

FBRX_OUT_7 [2025-03-19 12:36:36 -0400] 967 Bytes | 285 tokens | Cum: 1475 tkns (18.44% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update**Date: 2025-02-28Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/forte-biosciences-inc-nasdaqfbrx-short-interest-update-2025-02-27/Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 28,300 shares, a decrease of 79.0% from the January 31st total of 134,600 shares. Based on an average daily trading volume, of 546,400 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.6% of the shares of the stock are sold short.

Forte Biosciences Trading Down 0.2 %

Shares of FBRX stock traded down $0.02 during trading hours on Thursday, hitting $9.30. 24,145 shares of the company were exchanged, co

-- More? (MOR) or Next section? (NEX)

FBRX_IN_8 [2025-03-19 12:36:36 -0400] 3 Bytes | 2 tokens | Cum: 1477 tkns (18.46% of 8k)
==========================================================================

NEX

FBRX_OUT_9 [2025-03-19 12:36:38 -0400] 788 Bytes | 264 tokens | Cum: 1741 tkns (21.76% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-03-25T16:00:10Z - What Makes Forte Biosciences (FBRX) a New Buy Stock
B2 - 2023-12-13T13:29:24Z - Research Frontiers And 3 Other Stocks Under $1 Insiders Are Buying
B3 - 2023-12-11T13:34:01Z - RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying
B4 - 2023-11-24T11:38:00Z - Insiders Buying Vintage Wine Estates And 3 Other Stocks Under $1
B5 - 2023-04-06T19:53:22Z - Penny Stocks To Buy Now? 4 To Watch In April
B6 - 2022-07-13T08:59:07Z - Boeing, PriceSmart And 80 Biggest Movers From Yesterday

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

FBRX_IN_10 [2025-03-19 12:36:38 -0400] 2 Bytes | 2 tokens | Cum: 1743 tkns (21.79% of 8k)
==========================================================================

B1

FBRX_OUT_11 [2025-03-19 12:36:39 -0400] 415 Bytes | 124 tokens | Cum: 1867 tkns (23.34% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**What Makes Forte Biosciences (FBRX) a New Buy Stock**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2245625/what-makes-forte-biosciences-fbrx-a-new-buy-stockForte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

-- More? (MOR) or Next section? (NEX)

FBRX_IN_12 [2025-03-19 12:36:39 -0400] 20 Bytes | 4 tokens | Cum: 1871 tkns (23.39% of 8k)
==========================================================================

Next section please.

FBRX_OUT_13 [2025-03-19 12:36:41 -0400] 1114 Bytes | 323 tokens | Cum: 2194 tkns (27.43% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S3 - 2024-11-20 8-K Item1.01. Entry into a Material Definitive Agrmt.

Securities Purchase Agrmt

On November 19, 2024, Forte Biosciences, Inc. (the Company) entered into a Securities Purchase Agrmt (the Purchase Agrmt) for a private placement (the Private Placement) with certain q...

S4 - 2024-11-14 10-Q PART I F INANCIAL INFO

Item 1: Fin Stmnts

FORTE BIOSCIENCES, INC.

COND CONS BA LANCE SHEETS

(in thousands, except share and par value data)

September 30, 2024

December 31, 2023

(unaudited)

Assets

Curr assets:

Cash and cash equ...

S5 - 2024-11-14 8-K Item2.02. Results of Oper and Fin Cond.

On November 14, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 to this Curr...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

FBRX_IN_14 [2025-03-19 12:36:41 -0400] 2 Bytes | 2 tokens | Cum: 2196 tkns (27.45% of 8k)
==========================================================================

S3

FBRX_OUT_15 [2025-03-19 12:36:43 -0400] 967 Bytes | 224 tokens | Cum: 2420 tkns (30.25% of 8k)
==========================================================================

Showing S3 (chunk 1 of 6): S3:
Item1.01. Entry into a Material Definitive Agreement.

Securities Purchase Agreement

On November 19, 2024, Forte Biosciences, Inc. (the Company) entered into a Securities Purchase Agreement (the Purchase Agreement) for a private placement (the Private Placement) with certain qualified institutional buyers, institutional accredited investors and certain executive officers and senior management (each, a Purchaser and collectively, the Purchasers). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 4,931,389 shares of the Companys common stock, par value $0.001 per share (the Shares), at a purchase price of $5.552 per Share, representing the average of the Nasdaq Official Closing Price of the Companys Common Stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of the Purchase Agreement, and (ii) pre-funded wa

-- More? (MOR) or Next section? (NEX)

FBRX_IN_16 [2025-03-19 12:36:43 -0400] 3 Bytes | 2 tokens | Cum: 2422 tkns (30.28% of 8k)
==========================================================================

MOR

FBRX_OUT_17 [2025-03-19 12:36:44 -0400] 967 Bytes | 222 tokens | Cum: 2644 tkns (33.05% of 8k)
==========================================================================

Showing S3 (chunk 2 of 6): rrants (the Pre-Funded Warrants) to purchase 4,615,555 shares of Common Stock (the Warrant Shares and together with the Shares and the Pre-Funded Warrants, the Securities), at a purchase price of $5.551 per Pre-Funded Warrant, provided that each Purchaser may elect to change its allocation of Shares and Pre-Funded Warrants prior to closing. The Pre-Funded Warrants will have an exercise price of $0.001 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or such lower percentage as determined by each Purchaser. The holders of Pre-Funded Warrants may increase or decrease such percentages

-- More? (MOR) or Next section? (NEX)

FBRX_IN_18 [2025-03-19 12:36:44 -0400] 19 Bytes | 7 tokens | Cum: 2651 tkns (33.14% of 8k)
==========================================================================

Next section? (NEX)

FBRX_OUT_19 [2025-03-19 12:36:58 -0400] 3582 Bytes | 928 tokens | Cum: 3579 tkns (44.74% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Prev Close: 5.50 | RSI (14): 31.72 | Perf Quarter: -72.89% | Insider Trans: 1.87% | Sales Q/Q: - | ROE: -137.40% |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Target Price: 81.33 | ATR (14): 0.98 | Index: - | Option/Short: No / Yes | Sales past 5Y: 0.00% | ROI: -365.10% |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Price: 6.28 | SMA20: -16.46% | Market Cap: 40.11M | Short Float: 0.24% | Income: -34.20M | Sales Surprise: - |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Change: 14.09% | SMA50: -47.28% | Shs Outstand: 6.39M | Short Ratio: 0.31 | Employees: 9 | EPS Surprise: 28.32% |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Volume: 11,398 | SMA200: -46.29% | Shs Float: 5.17M | Short Interest: 0.01M | Debt/Eq: 0.00 | P/E: - |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Avg Volume: 39.67K | Perf Week: 7.82% | Inst Own: 69.10% | Beta: 2.64 | Sales Y/Y TTM: - | Earnings: Nov 14 AMC |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Rel Volume: 0.62 | Perf Month: -44.12% | Insider Own: 19.14% | Sales: 0.00M | Profit Margin: - | |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: Forte Biosciences, Inc. (FBRX) by Wagner Paul A. (SEE REMARKS) on 2025-01-01
- Common Stock: 1250 shares at $0 (D)
- Common Stock: 164 shares at $22.71 (D)
- Restricted Stock Units: 1250 shares at $0 (D)

Inside Trans: Forte Biosciences, Inc. (FBRX) by Riley Antony A (CHIEF FINANCIAL OFFICER) on 2025-01-01
- Common Stock: 375 shares at $0 (D)
- Common Stock: 154 shares at $22.71 (D)
- Restricted Stock Units: 375 shares at $0 (D)

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

FBRX_IN_20 [2025-03-19 12:36:58 -0400] 1170 Bytes | 252 tokens | Cum: 3831 tkns (47.89% of 8k)
==========================================================================

The overall performance of Forte Biosciences, Inc. (FBRX) shows a negative trend as it has a quarterly performance of -72.89% and a monthly performance of -44.12%. The Relative Strength Index (RSI) being below 50, at 31.72, suggests that the market is oversold and could be due for a correction. The company has a high level of institutional ownership at 69.1%, indicating strong confidence from sophisticated investors. However, the company's ROE and ROI are both negative, at -137.4% and -365.1% respectively, indicating poor profitability. Insider transactions show recent stock acquisitions by executives, which may indicate their confidence in the company's future. However, the company's sales and income figures are negative, suggesting the company is not generating profit.

Given the oversold condition indicated by the RSI, and recent insider transactions, there may be potential for a short-term upward price move. However, the company's poor profitability and negative sales figures suggest caution is warranted for long-term investment.

MARKET_SCORE[50]
PRICE_TARGET[$6.50]

AI_RPT_HEADLINE: "Forte Biosciences Fights Against Negative Profitability Trend"

FBRX_OUT_21 [2025-03-19 12:37:00 -0400] 561 Bytes | 131 tokens | Cum: 3962 tkns (49.53% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More financial metrics
-> X3 <- More SEC filings & insider data
-> X4 <- Broader sector & market news
-> X5 <- General market sentiment & AI confidence levels
-> X6 <- AI's past analysis on similar companies
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

FBRX_IN_22 [2025-03-19 12:37:00 -0400] 31 Bytes | 7 tokens | Cum: 3969 tkns (49.61% of 8k)
==========================================================================

-> X2 <- More financial metrics

FBRX_IN_23 [2025-03-19 12:37:01 -0400] 126 Bytes | 29 tokens | Cum: 3998 tkns (49.98% of 8k)
==========================================================================

====================================
[2025-03-19 09:37:01] # Analysis Completed
Elapsed Time: 40.85 seconds




Scroll to Top